Alzheimer s Research & Therapy · 2015 · 124 citations · 25 references
Life SciencesNeurologyNeuroscienceDementiaMonoclonal AntibodiesNeurodegenerationAlzheimer DiseaseCerebrospinal Fluid BiomarkersDementia BiomarkersDiagnostic Monoclonal AntibodiesNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer's Disease DiagnosisAmyloid Beta PeptidesAssayAssay SensitivityAssay SpecificityLower Limit Of QuantificationLower Limit Of QuantitationMonoclonal Antibody Assays
INTRODUCTION: Amyloid β-protein oligomers play a key role in Alzheimer's disease (AD), but well-validated assays that routinely detect them in cerebrospinal fluid (CSF) are just emerging. We sought to confirm and extend a recent study using the Singulex Erenna platform that reported increased mean CSF oligomer levels in AD. METHODS: We tested four antibody pairs and chose one pair that was particularly sensitive, using 1C22, our new oligomer-selective monoclonal antibody, for capture. We applied this new assay to extracts of human brain and CSF. RESULTS: A combination of 1C22 for capture and 3D6 for detection yielded an Erenna immunoassay with a lower limit of quantification of approximately 0.15 pg/ml that was highly selective for oligomers over monomers and detected a wide size-range of oligomers. Most CSFs we tested had detectable oligomer levels but with a large overlap between AD and controls and a trend for higher mean levels in mild cognitive impairment (MCI) than controls. CONCLUSION: Aβ oligomers are detectable in most human CSFs, but AD and controls overlap. MCI CSFs may have a modest elevation in mean value by this assay.
25
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Alzheimer's disease: synaptic dysfunction and Aβ
Ganesh M. Shankar, Dominic M. Walsh · Molecular Neurodegeneration · 2009 · 502 citations · Full text